Sign In
Buy ALPN
$64.97
+0 (+0%)
At Close: Aug 19, 2024
Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the European League Against Rheumatism
Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases at the EULAR
Alpine Immune Sciences : Announces Poster Presentations at EULAR 2020 | MarketScreener
12:05pm, Friday, 29'th May 2020Alpine Immune Sciences Announces Poster Presentations at EULAR 2020
12:00pm, Friday, 29'th May 2020
Alpine Immune Sciences Announces Poster Presentations at EULAR 2020
Alpine Immune Sciences : to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference | MarketScreener
08:06pm, Tuesday, 26'th May 2020Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
08:05pm, Tuesday, 26'th May 2020
Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
12:00am, Tuesday, 26'th May 2020
Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported Earnings, And Analysts Cut Their Target Price
12:11pm, Saturday, 16'th May 2020
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) just released its quarterly report and things are looking bullish. Sales...
ALPINE IMMUNE SCIENCES, INC. : Results of Operations and Financial Condition (form 8-K) | MarketScreener
08:22pm, Thursday, 14'th May 2020Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
08:01pm, Thursday, 14'th May 2020
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
12:00am, Thursday, 14'th May 2020
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
Alpine Immune Sciences presents design of NEON-1 study at AACR ALPN
04:48pm, Monday, 27'th Apr 2020
Alpine Immune Sciences presents design of NEON-1 study at AACR ALPN
Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I
01:00pm, Monday, 27'th Apr 2020
Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I
